Newsfeeds - Spark Newswire

4 minute read

Lantern Pharma Enters into Strategic Collaboration With Deep Lens; Terms Not Disclosed

Today, 11:14 AM

Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug

LTRN

1 minute read

Lantern Pharma’s LP-184 Receives Orphan Drug Tag For Brain Cancer Indication

By Vandana Singh

Today, 11:14 AM

The FDA has granted Orphan Drug Designation to Lantern Pharma Inc’s (NASDAQ:LTRN) LP-184 for glioblastoma multiforme (GBM) and…

LTRN

1 minute read

FDA Grants Lantern Pharma Additional Orphan Drug Designation For Drug Candidate LP-184 In Glioblastoma Multiforme & Malignant Gliomas

By Bill Haddad

Today, 11:14 AM

Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology

LTRN

5 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:14 AM

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently reported partial exercise of underwriter’s over-allotment option.

ABSI

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 11:14 AM

ABSI

6 minute read

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data

By Shanthi Rexaline

Today, 11:14 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19)

ABVC

1 minute read

Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock

By Vandana Singh

Today, 11:14 AM

Lantern Pharma Inc (NASDAQ:LTRN) announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve…

LTRN

12 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 11:14 AM

Thursday morning, 173 companies reached new 52-week lows.

AAMC

4 minute read

FDA
News

Lantern Pharma Announces Preclinical Data In Glioblastoma (GBM) With Drug Candidate LP-184 And Expands GBM Research Collaboration

By Benzinga Newsdesk

Today, 11:14 AM

Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in

LTRN